Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
12,37 USD | -0,88% | -7,13% | +31,46% |
09/02 | ENANTA PHARMACEUTICALS, INC. : Oppenheimer is neutraal gestemd over het aandeel | ZM |
07/02 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Omzet 2024 * | 68,81 mln. 64,36 mln. | Omzet 2025 * | 73,31 mln. 68,56 mln. | Marktkapitalisatie | 262 mln. 245 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -110 mln. -103 mln. | Nettowinst (verlies) 2025 * | -116 mln. -108 mln. | EV/omzet 2024 * | 3,8 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,57 x |
K/w-verhouding 2024 * |
-2,37
x | K/w-verhouding 2025 * |
-2,51
x | Werknemers | 145 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,9% |
Recentste transcriptie over Enanta Pharmaceuticals, Inc.
1 dag | -0,88% | ||
1 week | -7,13% | ||
Lopende maand | -29,15% | ||
1 maand | -22,45% | ||
3 maanden | +1,14% | ||
6 maanden | +46,56% | ||
Lopend jaar | +31,46% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 01-07-03 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 01-09-03 |
Chief Tech/Sci/R&D Officer | 50 | 08-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 29-06-20 |
Lesley Russell
BRD | Director/Board Member | 63 | 18-11-16 |
Bruce Carter
CHM | Chairman | 80 | 25-11-13 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.10% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 12,37 | -0,88% | 67 161 |
25-04-24 | 12,48 | -3,41% | 79 696 |
24-04-24 | 12,92 | -1,75% | 90 291 |
23-04-24 | 13,15 | -2,16% | 108 198 |
22-04-24 | 13,44 | +0,90% | 67 129 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+31,46% | 264 mln. | |
+1,51% | 42,59 mld. | |
+8,57% | 40,65 mld. | |
+49,22% | 40,57 mld. | |
-12,36% | 26,77 mld. | |
+8,92% | 24,81 mld. | |
-25,13% | 18,17 mld. | |
+29,17% | 12,05 mld. | |
-3,12% | 11,7 mld. | |
+6,35% | 11,1 mld. |